

Can Coronaviridae Viruses Reappear with their Novel Variants in Upcoming Years?

¹Rajesh Dhakane, ²Anant Shinde, ³Suchitra Bhattacharjee, ⁴Sopan Wagh

¹Department of Microbiology, Jayawantrao Sawant College of Commerce and Science, Hadapsar, Pune, India

²Department of Zoology, Yashwantrao Chavan Arts and Science Mahavidyalaya, Mangrulpir, India

³Department of Bioengineering, Stevens Institute of Technology, Castle Point Terrace, Hoboken, NJ, USA

⁴Department of Bioscience and Technology, Agri-biotech College, Aurangabad, India

Article Info

Article history:

Received on: March 31, 2020

Accepted on: April 13, 2020

Published on: April 22, 2020

Keywords: SARS-CoV2, COVID-19, Mutation, genetic makeup, SARS-CoV.

Corresponding Author:

Rajesh Dhakane

Email:

rajeshdhakane001@gmail.com

Abstract

SARS-CoV2, the infectious biological entity has made havoc across the globe and created a question mark on the survival of humans. This infectious agent is a variant of SARS-CoV spread in 2003 and more dangerous than previous infectious particles belonging to the same family. Biological objects get a mutation in their genetic makeup which is either beneficial or harmful. If a mutation is useful, the entity is selected by nature for survival. Such genetic changes are continuous processes, and organisms generate their variants. In this review, we have highlighted whether this theory is true regarding SARS-CoV2 or not. We have estimated the probability of reappearance of coronaviridae members in future with their variant forms.

© Copyright 2020 International Journal of Microbial Science

This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/) that permits noncommercial use of the work provided that credit must be given to the creator and adaptation must be shared under the same terms.

1. Introduction:

In human history, there are many cases of viral pandemic infections including polio [1], ebola [2], smallpox [3], chicken pox [4], HIV-AIDS [5], which had put human life on serious risk [3]. Nevertheless, owing to efforts taken by medical sectors across the globe, such diseases were controlled by either vaccine [6] or treatments [7] or some of them are reduced by prevention only [8]. The diseases mentioned above were life threatening and caused a potential biological loss in the world [9,10,11]. Of them, airborne and contagious diseases [12] are more challenging to humankind since they are challenging to control. It is true, especially in those countries where the

population is high, and awareness among people is less. Like other biological species, viruses are capable of altering their genetic makeup [13,14] and get chances of reappearances [13,14,15], hence making them more infectious than their parents [16]. The variation in genes results in altered protein sequence leading to changed functions of proteins [17]. The antiviral drugs available against these infections are not as productive as those were made to recognize only specific target sites [18]. As a result, the infectious particles go on infecting people continuously resulting in international health concern and panic with uncontrolled deaths.

According to Prajapat, M. et al. [19], there is only one Protein Data Bank (PDB ID:6LU7) on the 2019-nCoV, which forms a complex with the N3 inhibitor. However, the genome sequence shows that there is 95% similarity with the bat -SL-CoVZC45 and 88% to SIRS CoV-ZSc [19]. This study suggests that the changes have occurred in the amount of recombination process in 2019-nCoV and the protein structural and functional levels.

In this review, we analyzed the evolution of corona virus family (Coronaviridae) [20] to know the genetic similarity and variation patterns in relation with newly arrived Severe Acute Respiratory Syndrome (SARS-CoV2)virus, which infected 2,078,605 people from 213 areas, countries and territories with 139,515 deaths (table 1) till April 17, 2020. Till date, there is no vaccine or effective measure to stop its spread [16]. Apart from analyzing the evolutionary aspect, the article also discusses the probable genetic variation leading to substantial uncontrolled health risk to human life [13, 14] causing a higher uncontrolled health risk to humans.

2. Evolution and Future reappearance:

The viruses which contain RNA as their genetic material have potential to get evolved [21] and coronaviridae family has RNA as genetic material [22], which can evolve. In sequence, the viral genetic evolution has occurred in SARS-CoV that spreads through human to human contact [12] and this idea has been supported by [23]. They stated that SARS-CoV and SARS-CoV2 belong to a beta group of corona virus. They have 70% similarity at a genetic level showing DNA level differences among them (figure 1). This indicates that both viruses are 30% different in their genetic structure that is a result of mutations such as genetic recombination, gene deletion or insertion creating the probability of outbreak in future like its ancestors created in the past [16]. Likewise, genome level gene exchange, recombination [24], gene deletion or insertion may create a probability of outbreak in future, like past incidences [25] (figure 1) such as SARS CoV epidemics.

Additionally, SARS-CoV2 is considerably similar with SARS-CoV helping for predictions on occurred epidemic health disaster, and corona viruses may be responsible for outbreaks with variant mutations like previous one in upcoming

years [13, 14, 25] (Figure 1). This suggests that both types of corona viruses are genetic variants.

Table 1: Shows updated SARS-CoV2 infection status as on 17 April 2020 [26].

Sr. no.	Reported Cases/ Affected Regions	Number
1	Confirmed	2,078,605
2	Deaths	139,515
3	Number of Affected Countries, territories or areas	213

Besides, SARS-CoV and SARS-CoV2 are similar for their severity. This idea was supported by Huang, C., et al., Chen, N., et al., Wang, D., et al., [27, 28, 29] who proposed that SARS-CoV2 severity mimicked with previously spread SARS-CoV and they also share same clinical features [30]. Chaolin Huang et al. [31] supported our concept and stated that corona viruses might lead to substantially more novel as well as severe zoonotic incidences.

Moreover, clinical characters of 2019-nCoV showed similarity with previously studied beta coronavirus infections [31]. Features showed by 2019-nCoV infections revealed some resemblance with SARS-CoV as well as MERS-CoV infections [32, 33]. This strongly suggests that the novel coronavirus (SARS-V2) has evolved from previously observed SARS-CoV, a member of the betacoronavirus group.

Additionally, there is a difference between SARS and 2019-nCoV regarding immunogenicity as former causes pulmonary inflammation with high level lung damage whereas the second causes raised production of Th2 cytokines retarding inflammation [34]. This effect might be due to 17% genetic variation caused by 2019-nCoV in PL pro sequences. As a result, the international crisis has occurred and there is no proper vaccine or drug against it till writing this article.

In spite of 83% similarity in the PLpro sequences of SARS-CoV and SARS-CoV-2, both of them share active sites which are similar [35]. According to Huang, C. et al. [27], infections by SARS-CoV-2 and earlier betacoronavirus showed similarities in clinical characteristics. To add, sequence identity between SARS-CoV2 and betacoronavirus members regarding domains of

conserved replicase is lower than 90% [36] suggesting the relationship between both entities.




Figure 1: Schematic representation of the predicted evolution of Coronaviridae members with probable effects on human health. Note: 1a, 1b, 1c, 1d, 1e, 1f represent predicted evolutionary pathway of alpha, gamma, delta, toro and bafini viruses, respectively.

SARS-CoV-2 is considerably homologous to CoV that caused SARS (Severe Acute Respiratory Syndrome) during 2003. Also, SARS-CoV2 pathogen is more similar in relation with genetic makeup to SARS-CoV as compared with MERS-CoV [37, 38, 39]. As well, both have a common factor, i.e. human ACE2 receptor [39], which indicated that the genetic modifications in newly arrived pathogen do not affect human cell receptor recognition. With the exception, the COVID-19 pathogen binds human ACE2 more weakly with help of its S protein than SARS-CoV, causing less potential infection than SARS-CoV [37].

Furthermore, it was observed that death rate due to COVID-19 was found as 2% [40] while that of SARS spread in 2002, it was 10% [41] and in case of MERS, it was 37% [42]. It may be because of genetic modifications. Moreover, SARS-CoV has

same size as SARS-CoV-2 [43], and both have high homology [44] supporting morphological similarity among them.

Interestingly, over 95% sequences show a similarity between SARS-CoV2 3CLpro and RdRp protease with that of SARS-CoV, and both viruses have 79% genetic similarity in their sequences [39]. Besides, they share potentially conserved Receptor Binding Domain (RBD) along with S protein domain [35,37,45] which is due to recombination/mutation acquisition in SARS-CoV-2 [16]. To add, novel viral host cell entry and replication proteins are similar with that of SARS-CoV with respect to their structure [46].




Figure 2: Schematic representation of the predicted evolution of Coronaviridae members with probable effects on human health. Note: 2a, 2b, 2c, 2d represent predicted evolutionary pathway of 229E, OC43, NL63, HKU1 viruses, respectively.

Additionally, it is found that SARS-CoV2 is one of the seven coronaviruses that infect human beings and others are MERS-CoV, SARS-CoV (cause severe infection), 229E, OC43, NL63, HKU1 (cause mild symptoms) [49]. In future, genetic variations may occur in the last four types (figure 2). Since the COVID-19 pathogen has similarity with SARS-

CoV along with some symptoms, there is sense of its upcoming arrival [13, 14].

Out of six genera (ending with suffix 'virus') of family coronaviridae, i.e. alpha, beta, gamma, delta, toro and bafini [20], betacoronaviruses include SARS-CoV, MERS, SARS-CoV-2 [46] and SARS-CoV-2 is a novel coronavirus in the genus that is belonging to MERS-CoV and SARS-CoV (figure 1). Like MERS-CoV and SARS-CoV, SARS-CoV2 targets lower part of the respiratory system leading to pneumonia and it also infects heart, kidney, gastrointestinal system, liver as well as central nervous system [47, 48] showing pathological similarity. It means that the virus family understudy is genetically changeable and in upcoming decade, the same virus or other viruses of the same family will reappear [13, 14] with their genetic variants (figure 1).

3. Conclusion:

The coronavirus family is highly changing and its genetic variants may appear. In this sequence, genetic mutants of SARS-CoV2 may be detected in future.

Acknowledgement:

Authors are thankful to Dr Anant Shinde, Yashwantrao Chavan Arts and Science Mahavidyalaya, Mangrulpir, District-Washim, India for his support and motivation in writing this manuscript.

Author contributions: RD: Developed an idea and wrote the manuscript. AS: Verified the data. SB: Improved the manuscript. SW: Corrected the manuscript.

Conflict of interest: Authors declare that no conflict of interest exists regarding the writing of this article.

References:

- Chumakov, K., Ehrenfeld, E., Wimmer, E., & Agol, V. I. (2007). Vaccination against polio should not be stopped. *Nature reviews. Microbiology*, 5(12), 952–958. <https://doi.org/10.1038/nrmicro1769>
- Malvy, D., McElroy, A. K., de Clerck, H., Günther, S., & van Griensven, J. (2019). Ebola virus disease. *Lancet (London, England)*, 393(10174), 936–948. [https://doi.org/10.1016/S0140-6736\(18\)33132-5](https://doi.org/10.1016/S0140-6736(18)33132-5)
- Guharoy, R., Panzik, R., Noviaskey, J. A., Krenzelok, E. P., & Blair, D. C. (2004). Smallpox: clinical features, prevention, and management. *The Annals of pharmacotherapy*, 38(3), 440–447. <https://doi.org/10.1345/aph.1D272>
- Heininger, U., & Seward, J. F. (2006). Varicella. *Lancet (London, England)*, 368(9544), 1365–1376. [https://doi.org/10.1016/S0140-6736\(06\)69561-5](https://doi.org/10.1016/S0140-6736(06)69561-5)
- A, K., S, C., RB, S., H, V., SS, S., & A, G. (2016). A REVIEW ON: HIV AIDS. *Indian Journal of Pharmaceutical and Biological Research*, 4(03), 69–73. <https://doi.org/10.30750/ijpbr.4.3.9>
- Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015). Polio vaccination: past, present and future. *Future microbiology*, 10(5), 791–808. <https://doi.org/10.2217/fmb.15.19>
- Ogra, P. L., & Volovitz, B. (1987). Diagnosis and treatment of viral infections. *Bulletin of the New York Academy of Medicine*, 63(6), 475–483.
- Coffin, J. M. (1999). *Molecular biology of HIV. In: The Evolution of HIV* (Crandall K.A., ed.). pp. 3–40. Johns Hopkins University Press, Baltimore, MD.
- Hu, B., Zeng, L. P., Yang, X. L., Ge, X. Y., Zhang, W., Li, B., Xie, J. Z., Shen, X. R., Zhang, Y. Z., Wang, N., Luo, D. S., Zheng, X. S., Wang, M. N., Daszak, P., Wang, L. F., Cui, J., & Shi, Z. L. (2017). Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. *PLoS pathogens*, 13(11), e1006698. <https://doi.org/10.1371/journal.ppat.1006698>
- Dudas, G., Carvalho, L. M., Rambaut, A., & Bedford, T. (2018). MERS-CoV spillover at the camel-human interface. *eLife*, 7, e31257. <https://doi.org/10.7554/eLife.31257>
- Leopardi, S., Holmes, E. C., Gastaldelli, M., Tassoni, L., Priori, P., Scaravelli, D., Zamperin, G., & De Benedictis, P. (2018). Interplay between co-divergence and cross-species transmission in the evolutionary history of bat coronaviruses. *Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases*, 58, 279–289. <https://doi.org/10.1016/j.meegid.2018.01.012>
- Wang, N., Li, S. Y., Yang, X. L., Huang, H. M., Zhang, Y. J., Guo, H., Luo, C. M., Miller, M., Zhu, G., Chmura, A. A., Hagan, E., Zhou, J. H., Zhang, Y. Z., Wang, L. F., Daszak, P., & Shi, Z. L. (2018). Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China. *Virologica Sinica*, 33(1), 104–107. <https://doi.org/10.1007/s12250-018-0012-7>
- Nagy, P. D., & Simon, A. E. (1997). New insights into the mechanisms of RNA recombination. *Virology*, 235(1), 1–9. <https://doi.org/10.1006/viro.1997.8681>
- Rowe, C. L., Fleming, J. O., Nathan, M. J., Sgro, J. Y., Palmenberg, A. C., & Baker, S. C. (1997). Generation of coronavirus spike deletion variants by high-frequency recombination at regions of predicted RNA secondary structure. *Journal of virology*, 71(8), 6183–6190. <https://doi.org/10.1128/JVI.71.8.6183-6190.1997>
- Sahin, A.R., Erdogan, A., Mutlu Agaoglu, P., Dineri, Y., Cakirci, A.Y., Senel, M.E., et al. (2020). 2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. *EJMO*, 4(1):1-7. DOI: [10.14744/ejmo.2020.12220](https://doi.org/10.14744/ejmo.2020.12220)
- Cui, J., Li, F., & Shi, Z. L. (2019). Origin and evolution of pathogenic coronaviruses. *Nature reviews*.

Microbiology, 17(3),181–192.

<https://doi.org/10.1038/s41579-018-0118-9>

17. Bhattacharya, R., Rose, P. W., Burley, S. K., & Prlić, A. (2017). Impact of genetic variation on three dimensional structure and function of proteins. *PLoS one*, 12(3), e0171355. <https://doi.org/10.1371/journal.pone.0171355>
18. Salvati, A. L., De Dominicis, A., Tait, S., Canitano, A., Lahm, A., & Fiore, L. (2004). Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus. *Antimicrobial agents and chemotherapy*, 48(6), 2233–2243. <https://doi.org/10.1128/AAC.48.6.2233-2243.2004>
19. Prajapat, M., Sarma, P., Shekhar, N., Avti, P., Sinha, S., Kaur, H., Kumar, S., Bhattacharyya, A., Kumar, H., Bansal, S., & Medhi, B. (2020). Drug targets for corona virus: A systematic review. *Indian journal of pharmacology*, 52(1), 56–65. https://doi.org/10.4103/ijp.IJP_115_20
20. Phan, M., Ngo Tri, T., Hong Anh, P., Baker, S., Kellam, P., & Cotten, M. (2018). Identification and characterization of Coronaviridae genomes from Vietnamese bats and rats based on conserved protein domains. *Virus evolution*, 4(2), vey035. <https://doi.org/10.1093/ve/vey035>
21. Moya, A., Elena, S. F., Bracho, A., Miralles, R., & Barrio, E. (2000). The evolution of RNA viruses: A population genetics view. *Proceedings of the National Academy of Sciences of the United States of America*, 97(13), 6967–6973. <https://doi.org/10.1073/pnas.97.13.6967>
22. Dave Cavanagh (2005). Coronaviridae: a review of coronaviruses and toroviruses. Coronaviruses with Special Emphasis on First Insights Concerning SARS 1 ed. by A. Schmidt, M.H. Wolff and O. Weber © 2005 Birkhäuser Verlag Basel/Switzerland.
23. Gralinski, L. E., & Menachery, V. D. (2020). Return of the Coronavirus: 2019-nCoV. *Viruses*, 12(2), 135. <https://doi.org/10.3390/v12020135>
24. Hu, B., Zeng, L. P., Yang, X. L., Ge, X. Y., Zhang, W., Li, B., Xie, J. Z., Shen, X. R., Zhang, Y. Z., Wang, N., Luo, D. S., Zheng, X. S., Wang, M. N., Daszak, P., Wang, L. F., Cui, J., & Shi, Z. L. (2017). Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. *PLoS pathogens*, 13(11), e1006698. <https://doi.org/10.1371/journal.ppat.1006698>
25. Sahin AR, Erdogan A, Mutlu Agaoglu P, Dineri Y, Cakirci AY, Senel ME, et al. (2019). Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. *EJMO*, 4(1):1-7. (Repeated)
26. World Health Organization (WHO) (2020). <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. Last updated 17 April, 2020.
27. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., ... Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*, 395(10223),497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
28. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet (London, England)*, 395(10223),507–513. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
29. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*, 323(11),1061–1069. <https://doi.org/10.1001/jama.2020.1585>
30. Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., Liu, L., Shan, H., Lei, C. L., Hui, D., Du, B., Li, L. J., Zeng, G., Yuen, K. Y., Chen, R. C., Tang, C. L., Wang, T., Chen, P. Y., Xiang, J., Li, S. Y., ... China Medical Treatment Expert Group for Covid-19 (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine*, 382(18),1708–1720. <https://doi.org/10.1056/NEJMoa2002032>
31. Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang, Guohui Fan, Jiuyang Xu, Xiaoying Gu, Zhenshun Cheng, Ting Yu, Jiaan Xia, Yuan Wei, Wenjuan Wu, Xuelei Xie, Wen Yin, Hui Li, Min Liu, Yan Xiao, Hong Gao, Li Guo, Jungang Xie, Guangfa Wang, Rongmeng Jiang, Zhancheng Gao, Qi Jin, Jianwei Wang, Bin Cao. (January 24, 2020). Clinical features of patients infected with 2019 novel corona virus in Wuhan, China. *Lancet*, 395: 497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
32. Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., Lui, S. F., Szeto, C. C., Chung, S., & Sung, J. J. (2003). A major outbreak of severe acute respiratory syndrome in Hong Kong. *The New England journal of medicine*, 348(20), 1986–1994. <https://doi.org/10.1056/NEJMoa030685>
33. Assiri, A., Al-Tawfiq, J. A., Al-Rabeeh, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., Makhdoom, H. Q., Zumla, A. I., & Memish, Z. A. (2013). Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *The Lancet. Infectious diseases*, 13(9),752–761. [https://doi.org/10.1016/S1473-3099\(13\)70204-4](https://doi.org/10.1016/S1473-3099(13)70204-4)
34. Wong, C. K., Lam, C. W., Wu, A. K., Ip, W. K., Lee, N. L., Chan, I. H., Lit, L. C., Hui, D. S., Chan, M. H., Chung, S. S., & Sung, J. J. (2004). Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clinical and experimental immunology*, 136(1), 95–103. <https://doi.org/10.1111/j.1365-2249.2004.02415.x>
35. Morse, J. S., Lalonde, T., Xu, S., & Liu, W. R. (2020). Learning from the Past: Possible Urgent Prevention and Treatment

Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. *Chembiochem : a European journal of chemical biology*, 21(5),730–738.

<https://doi.org/10.1002/cbic.202000047>

36. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., Tan, W., & China Novel Coronavirus Investigating and Research Team (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. *The New England journal of medicine*, 382(8), 727–733. <https://doi.org/10.1056/NEJMoa2001017>
37. Dong N, Yang X, Ye L, Chen K, Chan EW-C, Yang M, et al. (2020). Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China, DOI:<https://doi.org/10.1101/2020.01.20.913368>
(This article is a preprint and has not been certified by peer review)
38. Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., Zhong, W., & Hao, P. (2020). Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Science China. Life sciences*, 63(3),457–460. <https://doi.org/10.1007/s11427-020-1637-5>
39. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., ... Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet (London, England)*, 395(10224), 565–574. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
40. Yi, Y., Lagniton, P., Ye, S., Li, E., & Xu, R. H. (2020). COVID-19: what has been learned and to be learned about the novel coronavirus disease. *International journal of biological sciences*, 16(10),1753–1766. <https://doi.org/10.7150/ijbs.45134>
41. World Health Organization website. (2003). Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 (based on data as of December 31, 2003). www.who.int/csr/sars/country/table2004_04_21/en/
Accessed January 19, 2020.
42. WHO (2019). MERS SITUATION UPDATE. <http://applications.emro.who.int/docs/EMRPUB-CSR-241-2019-EN.pdf?ua=1&ua=1&ua=1>
43. Balazy, A., Toivola, M., Adhikari, A., Sivasubramani, S. K., Reponen, T., & Grinshpun, S. A. (2006). Do N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks?. *American journal of infection control*, 34(2), 51–57. <https://doi.org/10.1016/j.ajic.2005.08.018>
44. Zhang Y-Z. (2019). Novel 2019 coronavirus genome. <http://virological.org/t/novel-2019-coronavirusgenome/319>
45. Chan, J. F., Kok, K. H., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. Y. (2020). Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerging microbes & infections*, 9(1), 221–236. <https://doi.org/10.1080/22221751.2020.1719902>
46. Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., & Albaiu, D. (2020). Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. *ACS central science*, 6(3), 315–331. <https://doi.org/10.1021/acscentsci.0c00272>
47. Su, S., Wong, G., Shi, W., Liu, J., Lai, A., Zhou, J., Liu, W., Bi, Y., & Gao, G. F. (2016). Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. *Trends in microbiology*, 24(6), 490–502. <https://doi.org/10.1016/j.tim.2016.03.003>
48. Zhu N, Zhang D, Wang W, et al. (2020). A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*, 382:727-33.
49. Corman, V. M., Muth, D., Niemeyer, D., & Drosten, C. (2018). Hosts and Sources of Endemic Human Coronaviruses. *Advances in virus research*, 100, 163–188. <https://doi.org/10.1016/bs.aivir.2018.01.001>

Cite this article as: Dhakane, R., Shinde, A., Bhattacharjee, S., & Wagh, S. 2020. Can Coronaviridae Viruses Reappear with their Novel Variants in Upcoming Years? *International Journal of Microbial Science*, 1(1):1-6.

